NEW YORK (TheStreet) -- Acadia Pharmaceuticals (ACAD) - Get Report stock is slumping by 0.02% to $27.04 in after-hours trading on Thursday, after reporting a wider-than-expected 2016 first quarter loss. 

After the market close, the biopharmaceutical company reported an adjusted loss of 45 cents per share, compared to analysts' estimates for a loss of 42 cents per share. 

Research and development expenses climbed to $22.8 million for the most recent period, from $16.3 million a year ago. General and administrative costs climbed to $27.5 million, up  from $24.3 million in the year-ago period. 

"We are very excited about the recent FDA approval of NUPLAZID™," CEO Steve Davis said in a statement. "For the first time, physicians will have a drug to treat hallucinations and delusions without worsening motor function in Parkinson's psychosis patients. We look forward to making NUPLAZID available to physicians and patients in June."

Separately, TheStreet Ratings team rates the stock as a "sell" with a ratings score of D.

Acadia's weaknesses include its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself.

You can view the full analysis from the report here: ACAD

TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this article's author. 

Image placeholder title